- 期刊
- OpenAccess
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
並列摘要
Treatment of castration-resistant prostate cancer remains an area of unmet medical need. Evidence suggests that this entity continues to be driven by androgens and androgen receptor (AR) signaling. Abiraterone acetate, a pregnenolone derivative, is an oral selective and irreversible inhibitor of the key steroidogenic enzyme CYP17. It possesses dual 17-α hydroxylase and C17,20-lyase blocking activity, the result of which is decreased gonadal and extra-gonadal androgen synthesis. Abiraterone was first approved by the US Food and Drug Administration (FDA) in 2011 following the demonstration of superior survival compared with placebo in the post-docetaxel population. Since that time, more evidence has been generated from preclinical studies and clinical trials which have considerably enhanced our understanding of this complex disease. In this paper, we review the development of abiraterone acetate, its pharmacological characteristics, and its effects on the androgen-AR signaling axis, along with the combined experience from clinical trials. We also discuss some of the ongoing trials using this agent, as well as potential mechanisms of abiraterone resistance, novel biomarker development, and future directions using AR-directed therapies.
延伸閱讀
- Shoushtari, A. N., Landa, J., Kuk, D., Sanchez, A., Lala, B., Schmidt, N., Okoli, C., Chi, P., Dickson, M. A., Gounder, M. M., Keohan, M. L., Crago, A. M., Tap, W. D., & D'Angelo, S. P. (2016). Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma. Sarcoma, 2016(), 82-89. https://doi.org/10.1155/2016/3547497
- Guo, D. J., Zhang, K. Y. H., Chen, X. L., Chen, X. Z., Zhang, B., Zhou, Z. G., & Hu, J. K. (2015). Prognostic Value of Metastatic No.8p LNs in Patients with Gastric Cancer. Gastroenterology Research and Practice, 2015(), 784-790-206. https://doi.org/10.1155/2015/937682
- Amm, J. E., & Ching, J. B. A. (2016). Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, (), 11-19. https://doi.org/10.4137/CMO.S30751
- Hsieh, T. S., Chen, J., Tsai, T. C., & Chen, Y. W. (1991). Clinical Evaluation of Advanced Prostate Cancer Treated with LH-RH Analogue. 中華民國泌尿科醫學會雜誌, 2(3), 531-535. https://doi.org/10.7024/JUAROC.199109.0531
- Amm, J. E., Patel, N., Freeman, A., & Ching, J. B. A. (2013). Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide. Clinical Medicine Insights: Oncology, (), 235-245. https://doi.org/10.4137/CMO.S11670